Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30506-3. doi: 10.1016/j.bbmt.2019.07.034. [Epub ahead of print]

Preventing Measles among Immunosuppressed Cancer and Hematopoietic Cell Transplant Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy.

Author information

1
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington School of Medicine, Seattle, WA. Electronic address: spergam@fredhutch.org.
2
Department of Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA.
3
Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
4
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.
5
Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
6
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington School of Medicine, Seattle, WA.
7
Department of Medicine, Vanderbilt University, Nashville, TN.
8
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
9
Division of Infectious Diseases, City of Hope National Medical Center, Duarte, CA.
10
Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Health Services, Alberta, Canada.
11
Department of Medicine, University of Washington School of Medicine, Seattle, WA; Public Health - Seattle & King County, Seattle, Washington.
12
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA. Electronic address: pcarpent@fredhutch.org.

Abstract

Until recently, measles exposures were relatively rare, and so consequently, were an afterthought for cancer and/or blood and marrow transplant recipients and their providers. Declines in measles herd immunity have reached critical levels in many communities throughout the US, due to increasing vaccine hesitancy, so that community-based outbreaks have occurred. The reemergence of measles as a clinical disease has raised serious concern among immunocompromised patients and those who work within the cancer and hematopoietic cell transplant (HCT) community. Since live attenuated vaccines such as measles mumps rubella (MMR) are contraindicated in immunocompromised patients and without approved antiviral therapies for measles, community exposures in these patients can lead to life-threatening infection. The lack of data regarding measles prevention in this population poses a number of clinical dilemmas. Herein, specialists in Infectious Diseases and HCT/cellular therapy endorsed by the American Society of Transplant and Cellular Therapy, address frequently asked questions about measles in these high-risk cancer and HCT patients, and provide their expert opinion based on the limited available data.

KEYWORDS:

Hematopoietic cell transplant; MMR; Measles; Outbreak; Vaccination

PMID:
31394271
DOI:
10.1016/j.bbmt.2019.07.034

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center